Artiva Biotherapeutics, Inc. (ARTV)
| Market Cap | 414.94M +787.1% |
| Revenue (ttm) | n/a |
| Net Income | -87.07M |
| EPS | -3.55 |
| Shares Out | 48.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,432,259 |
| Open | 8.61 |
| Previous Close | 8.00 |
| Day's Range | 8.10 - 8.83 |
| 52-Week Range | 1.47 - 14.53 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.80 (+319.2%) |
| Earnings Date | May 8, 2026 |
About ARTV
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/mic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ARTV stock is "Strong Buy." The 12-month stock price target is $35.8, which is an increase of 319.20% from the latest price.
News
Artiva Biotherapeutics Transcript: Status update
AlloNK, a novel NK cell therapy, shows promising efficacy and durability in highly refractory RA and other autoimmune diseases, with a favorable safety profile and potential for first-in-class approval. A pivotal phase III trial is planned, supported by strong financial resources.
Artiva Biotherapeutics Press release: Status update
Artiva Biotherapeutics issued a press release on June 8, 2026, disclosing material business information to investors.
Artiva Biotherapeutics highlights AlloNK data presented at EULAR 2026
Artiva Biotherapeutics (ARTV) highlighted clinical, safety and translational data for AlloNK, also known as AB-101, an allogeneic, off-the-shelf, non-genetically modified natural killer cell therapy c...
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic scleros...
Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted strong efficacy and durability data for a novel deep B-cell depletion therapy in refractory RA, with a pivotal trial set to start in late 2024 and read out in 2028. Recent financing secures operations through key milestones and supports expansion into additional autoimmune indications.
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapie...
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple ...
Artiva Biotherapeutics price target raised to $41 from $18 at Needham
Needham analyst Gil Blum raised the firm’s price target on Artiva Biotherapeutics (ARTV) to $41 from $18 and keeps a Buy rating on the shares after the company’s initial Clinical…
Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Artiva Biotherapeutics (ARTV) to $40 from $23 and keeps an Outperform rating on the shares. First results for AlloNK plus…
Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Artiva Biotherapeutics (ARTV) to $35 from $15 and keeps a Buy rating on the shares after the company announced initial results from…
Artiva Biotherapeutics Earnings release: Q1 2026
Artiva Biotherapeutics released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Artiva Biotherapeutics Quarterly report: Q1 2026
Artiva Biotherapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)
“Artiva has reached an important inflection point, with positive initial clinical data across multiple autoimmune diseases and FDA alignment on a single Phase 3 registrational trial design in refracto...
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...
Artiva reports data from clinical trials evaluating AlloNK
Artiva Biotherapeutics (ARTV) announced positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab. As of the April 3 data cutoff, the initial clinical...
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket t...
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial
Artiva Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel NK cell therapy for RA is advancing, with upcoming efficacy data in late-line patients and a focus on deep B-cell depletion, safety, and scalability. The approach aims for durable, one-time treatment and first-mover advantage in a significant unmet need population.
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therap...
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026
Artiva Biotherapeutics Earnings release: Q4 2025
Artiva Biotherapeutics released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.
Artiva Biotherapeutics Annual report: Q4 2025
Artiva Biotherapeutics has published its Q4 2025 annual report on March 10, 2026.
Artiva Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Deep B-cell depletion is positioned as a transformative approach for autoimmune diseases, with a lead focus on refractory rheumatoid arthritis due to high unmet need and first-mover potential. Early data show strong efficacy, favorable safety, and scalable, community-friendly administration, with pivotal trial plans and FDA discussions set for 2026.
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapi...